Securing Phase III Clinical Supply Through Rapid API‑in‑Capsule Manufacture

A Japanese multinational pharmaceutical company required on-time Phase III clinical supply of 500,000 API‑in‑capsule units, despite starting with no formulation, process, or equipment in place. At Arcinova, we accelerated development, rapidly established GMP manufacturing, and delivered 40 batches at scale while simultaneously building a validated process ready for late‑stage development.

Request to download the case study: Securing Phase III Clinical Supply Through Rapid API‑in‑Capsule Manufacture today.